Innorini Life Sciences launches Nasodine to Singapore healthcare professionals

Written By Rishi Bharadwaj

We’re thrilled to announce that Innorini has partnered with Firebrick Pharma, a leader in pharmaceutical innovation, to bring Nasodine®Nasal Spray, the world’s first PVP-I nasal spray, to healthcare professionals (HCPs) in Singapore!

Firebrick Pharma, a publicly listed Australian pharmaceutical company, focuses on developing and commercialising novel formulations using Povidone-Iodine. After over 10 years of R&D and multiple clinical trials, Firebrick’s first product is now available for patient use in Singapore. Innorini will lead Nasodine’s introduction to doctors and other HCPs in Singapore and aims to make this breakthrough product accessible to end users via the HCP channel.

Nasodine, a broad-spectrum antimicrobial nasal spray, has proven clinical safety and efficacy in a range of clinical settings. In Singapore, it will be promoted as a nasal antiseptic to GPs and hospitals for use in the management of respiratory infections, such as colds and flu, and for the eradication of MRSA in the nasal passages to reduce the risk of surgical site infections.

🔑 Key Benefits of Nasodine:

  • First-in-class PVP-I nasal spray

  • Proven to kill viruses and bacteria that cause colds and flu

  • Stops viral and bacterial shedding from the nose

  • Targets the microbial cause, not the symptoms of colds and flu

  • Does not contribute to antimicrobial resistance (AMR)

  • Clinically proven safety and peer-reviewed published data

  • Highly effective against antibiotic-resistant bacteria, with no resistance potential

At Innorini, we are passionate about healthcare innovation. By working with Firebrick, we’re excited to introduce a first-in-class breakthrough product like Nasodine to doctors and hospitals in Singapore.

💻 Purchase Nasodine at nasodine-sg.com.

👩‍⚕️ For Healthcare Professionals: Visit innorini.com.sg/healthcare-professionals to learn more and contact us for procurement information.

#InnoriniLifeSciences #FirebrickPharma #Nasodine #HealthcareInnovation #SingaporeLaunch #PharmaceuticalInnovation

Rishi Bharadwaj